Answers are grounded in this paper and cite their sources.
Background: Fog-in-Place (FIP) is a convenient process-level term for automated airborne distribution of treatment media within industrial and animal-housing environments. It is not a standardized technology class, a formulation identity, or evidence of efficacy. Objectives: To critically integrate aerosol physics, peer-reviewed food-industry observations, microbial surface validation, arthropod ecology, European biocidal regulation and risk governance. Methods: A targeted, non-systematic critical review of identifiable primary studies, standards and legislation was combined with a transparent reduced-order deposition model. Results: Published experiments indicate pronounced dependence of treatment on droplet diameter and surface orientation; upward-facing surfaces may be more responsive than vertical or downward-facing targets. Standards for automated airborne room disinfection provide defined microbiological carrier tests, but no direct ovicidal or acaricidal validation. An illustrative model reveals how orientation, shielding and ventilation can create persistent underexposure despite plausible room-average aerosol concentration. Conclusion: FIP should be evaluated as a coupled equipment–medium–environment–target process. Claims of broad-spectrum efficacy, including eggs, larvae, nymphs and adults of arthropods, require separate organism - and stage-specific field evidence. No confidential operational identity, chemistry or formulation is disclosed.
No takes yet. Share an insight, caveat, or question.
Jose Manuel López (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: